Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Article in English | MEDLINE | ID: mdl-21190819

ABSTRACT

We undertook this study to determine the role of Microsomal PGE Synthase-1 (mPGES-1), and mPGES-1-generated Prostaglandin (PG) E2 on Dendritic Cell (DC) phenotype and function. Using mPGES-1 KnockOut (KO) mice, we generated bone marrow derived DCs and determined their eicosanoid production profile, cell surface marker expression, and cytokine production. We also assessed DC migratory and functional capacity in vivo. Compared to wild-type, mPGES-1 deficient DCs exhibited a markedly attenuated increase in PGE2 production upon LPS stimulation, and displayed preferential shunting towards PGD2 production. mPGES-1 KO DCs did not display deficiencies in maturation, migration or ability to sensitize T cells. However, mPGES-1 deficient DCs generated reduced amounts of the Th1 cytokine IL-12, which may in part be due to increased PGD2 rather than decreased PGE2. These findings provide useful information on the effects of inducible PGE2 on the innate immune system, and have important implications regarding potential consequences of pharmacologic mPGES-1 inhibition.


Subject(s)
Cytokines/metabolism , Dendritic Cells/metabolism , Dinoprostone/biosynthesis , Intramolecular Oxidoreductases/genetics , Animals , Cell Movement/genetics , Cricetinae , Gene Deletion , Interleukin-12/metabolism , Intramolecular Oxidoreductases/metabolism , Lipopolysaccharides/pharmacology , Mice , Mice, Knockout , Prostaglandin-E Synthases , Rats
2.
Am J Cardiol ; 80(5A): 30E-34E, 1997 Sep 04.
Article in English | MEDLINE | ID: mdl-9296467

ABSTRACT

The safety and efficacy of weight-adjusted, low-molecular-weight heparin (dalteparin) was compared with that of unfractionated heparin during 6 days of treatment in 1,482 patients with unstable angina or non-Q-wave myocardial infarction. Dalteparin, at a lower dose, was compared with placebo during the following 39 days. No significant outcome difference was found between the 2 treatment regimens in the unblinded phase (days 1-6). Between days 6-45 the rates of death, myocardial infarction, and recurrence of angina were comparable between the active treatment and placebo groups. The results suggest that twice-daily administration of subcutaneous dalteparin may be an effective and safe alternative to unfractionated heparin during the acute phase of unstable coronary artery disease. Prolonged treatment with dalteparin at a lower once-daily dose did not confer any additional benefit over aspirin (75-165 mg) alone.


Subject(s)
Angina, Unstable/drug therapy , Anticoagulants/therapeutic use , Dalteparin/therapeutic use , Myocardial Infarction/drug therapy , Angina, Unstable/mortality , Anticoagulants/administration & dosage , Dalteparin/administration & dosage , Humans , Injections, Subcutaneous , Myocardial Infarction/mortality , Prospective Studies , Survival Analysis , Treatment Outcome
3.
Circulation ; 96(1): 61-8, 1997 Jul 01.
Article in English | MEDLINE | ID: mdl-9236418

ABSTRACT

BACKGROUND: Low-molecular-weight heparin has a number of pharmacological and pharmacokinetic advantages over unfractionated heparin that make it potentially suitable, when used in combination with aspirin, for the treatment of unstable coronary artery disease. METHOD AND RESULTS: Patients with unstable angina or non-Q-wave myocardial infarction (1482) were included in the study, which had two phases. In an open, acute phase (days 1 to 6), patients were assigned either twice-daily weight-adjusted subcutaneous injections of dalteparin (120 i.u./kg) or dose-adjusted intravenous infusion of unfractionated heparin. In the double-blind, prolonged treatment phase (days 6 to 45), patients received subcutaneously either dalteparin (7500 i.u. once daily) or placebo. During the first 6 days, the rate of death, myocardial infarction, or recurrence of angina was 7.6% in the unfractionated heparin-treated patients and 9.3% in the dalteparin-treated patients (relative risk, 1.18; 95% confidence interval [CI], 0.84 to 1.66). The corresponding rates in the two treatment groups for the composite end point of death or myocardial infarction were 3.6% and 3.9%, respectively (relative risk, 1.07; 95% CI, 0.63 to 1.80). Revascularization procedures were undertaken in 5.3% and 4.8% of patients in unfractionated heparin and dalteparin groups, respectively (relative risk, 0.88; 95% CI, 0.57 to 1.35). Between days 6 and 45, the rate of death, myocardial infarction, or recurrence of angina was 12.3% in both the placebo and dalteparin groups (relative risk, 1.01; 95% CI, 0.74 to 1.38). The corresponding rates for death or myocardial infarction were 4.7% and 4.3% (relative risk, 0.92; 95% CI, 0.54 to 1.57). Revascularization procedures were undertaken in 14.2% and 14.3% of patients in the placebo and dalteparin groups, respectively. CONCLUSIONS: Our results add to previous evidence suggesting that the low-molecular-weight heparin dalteparin administered by twice-daily subcutaneous injection may be an alternative to unfractionated heparin in the acute treatment of unstable angina or non-Q-wave myocardial infarction. Prolonged treatment with dalteparin at a lower once-daily dose in our study did not confer any additional benefit over aspirin (75 to 165 mg) alone.


Subject(s)
Angina, Unstable/drug therapy , Anticoagulants/therapeutic use , Dalteparin/therapeutic use , Heparin/therapeutic use , Myocardial Infarction/drug therapy , Adult , Aged , Aged, 80 and over , Aspirin/administration & dosage , Blood Coagulation Tests , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Injections, Intravenous , Injections, Subcutaneous , Male , Middle Aged , Patient Compliance , Prospective Studies , Treatment Outcome
4.
Leukemia ; 10(7): 1198-208, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8684002

ABSTRACT

Concurrent activation of BCL2 and MYC usually occurs in B cell non-Hodgkin lymphoma (B-NHL) by translocation of both oncogenes to both immunoglobulin heavy chain (IGH) alleles: this abrogates immunoglobulin synthesis. We have studied three B-NHL cell lines (DoHH2, VAL and ROS 50) and show that concurrent activation of BCL2 and MYC may follow translocation of both oncogenes to the same IGH allele. Conventional cytogenetics of DoHH2 suggested the presence of a t(14;18)(q32;q21) translocation. However, fluorescent in situ hybridization (FISH) studies using whole chromosome paints, alpha satellite probes and flow-sorted chromosomes as probes revealed an unexpected complexity of rearrangements involving chromosomes 8, 14 and 18, namely t(8;14;18)(q24;q32;q21). DNA blot and previous PCR analysis confirmed the juxtaposition of BCL2 major breakpoint region (mbr) with IGJH6, but also demonstrated a rearrangement within the first exon of MYC. The centromeric (5') MYC rearranged fragment comigrated with the BCL2-JH6 rearranged fragment in BamHI, EcoRI and Bg/II restriction digests. The der(8)t(8;14;18) therefore comprised 5' MYC (exon I)-Sgamma4-JH6-BCL2 mbr. Similar rearrangements were observed in both ROS 50 and VAL cell lines which contained two and three copies of the der(8)t(8;14;18) respectively. Quantitative flow cytometry for BCL2 and MYC expression showed abundant expression of both proteins in all three lines. These data indicate the der(14)t(14;18)(q32;q21) may itself be the target for any second translocation. The presence of the intact BCL2-JH fusion gene on the der(8)t(8;14;18) allowed concurrent activation of both BCL2 and MYC with no loss of immunoglobulin expression.


Subject(s)
Gene Expression Regulation, Neoplastic , Genes, myc , Immunoglobulin Heavy Chains/genetics , Lymphoma, B-Cell/genetics , Proto-Oncogene Proteins/genetics , Proto-Oncogenes/genetics , Translocation, Genetic , Aged , Alleles , Chromosome Mapping , Chromosomes, Human, Pair 14 , Chromosomes, Human, Pair 18 , Chromosomes, Human, Pair 8 , Female , Humans , In Situ Hybridization, Fluorescence , Lymphoma, B-Cell/immunology , Male , Middle Aged , Proto-Oncogene Proteins c-bcl-2 , Tumor Cells, Cultured
5.
Ann Vasc Surg ; 6(1): 45-9, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1547076

ABSTRACT

We have developed a protocol for nonoperative management of pseudoaneurysms and arteriovenous fistulas secondary to cardiac catheterization. Hemodynamically stable patients were placed at bed rest and underwent serial physical examination, hematocrit, and duplex ultrasonography for a minimum of three days prior to discharge and subsequently as outpatients. Sixteen initially stable patients out of 56 with femoral artery catheter trauma managed over a four-year period underwent deliberate conservative management. Their lesions included six arteriovenous fistulas, seven pseudoaneurysms, and three patients with both complications. All but one of the pseudoaneurysms resolved spontaneously within four weeks regardless of initial size or associated arteriovenous fistula. One patient receiving anticoagulant therapy required surgery for bleeding after a three-day period of observation of a pseudoaneurysm. Six of the nine arteriovenous fistulas also resolved within the initial period of observation. The remaining three have been followed for four to 20 months and have remained asymptomatic. Nonoperative therapy of catheter-related femoral artery trauma is both safe and effective. Conservative management avoids potential wound complications associated with dissection through surrounding hematoma as well as the additional hospitalization required for postoperative care. We recommend a period of observation for all hemodynamically stable patients with catheter-induced pseudoaneurysms and arteriovenous fistulas of the femoral vessels, with surgery reserved for hemorrhage, expanding masses, or compromised cardiac output.


Subject(s)
Femoral Artery/injuries , Iatrogenic Disease , Aneurysm/diagnostic imaging , Aneurysm/etiology , Aneurysm/therapy , Arteriovenous Fistula/diagnostic imaging , Arteriovenous Fistula/etiology , Arteriovenous Fistula/therapy , Bed Rest , Cardiac Catheterization/adverse effects , Cardiac Catheterization/instrumentation , Cardiac Catheterization/methods , Femoral Artery/diagnostic imaging , Hematoma/diagnostic imaging , Hematoma/etiology , Hematoma/therapy , Humans , Remission, Spontaneous , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...